No Data
Doray Pharmaceuticals (301075.SZ): The target of the acquisition has passed the pharmaceutical GMP compliance inspection and the active pharmaceutical ingredient has been approved for listing.
Gelonghui Nov 6th │ Duorui Pharmaceuticals (301075.SZ) announced that recently, the company's controlling subsidiary, Changdu Rui Le Kang Enterprise Management Co., Ltd., intends to acquire the subject Sichuan FrontBio Pharmaceutical Co., Ltd., approved by the National Medical Products Administration to issue the "Chemical Raw Materials Pharmaceuticals Market Application Approval Notice" (No.: 2024YS01126), approved for domestic production of Ecokin chemical raw materials pharmaceuticals; at the same time, Sichuan FrontBio recently received the "Pharmaceutical GMP Compliance Inspection Notice" (Chuanxu 2024179) issued by the Sichuan Provincial Medical Products Administration, Ecokin active pharmaceutical ingredient production line has passed.
Duorui Pharmaceuticals (301075.SZ): Intends to transfer 5.66% equity of Hubei Tianji for 68.8 million yuan.
Adlinsight November 4th | Dorley Pharmaceuticals (301075.SZ) announced that on November 4, 2024, the board of directors held the seventeenth meeting of the second session and the board of supervisors held the sixteenth meeting of the second session, deliberating and approving the "Proposal on transferring all equity of the equity-participating company and signing the Equity Transfer Agreement", agreeing to transfer the 5.66% equity held in Hubei Tianji Pharmaceutical Co., Ltd. (hereinafter referred to as "Hubei Tianji") for a total of RMB 68.8 million to Hubei Qingsong Yueyue Medicine Co., Ltd. (hereinafter referred to as "Qingsong Yueyue"). After the completion of the above transaction, the company will no longer hold equity in Hubei Tianji.
Duorui Pharmaceutical (301075.SZ): Linsidomine sodium acetate injection passed the consistency evaluation.
DuoRui Pharmaceutical (301075.SZ) announced that its wholly-owned subsidiary Hubei DuoRui Pharmaceutical Co., Ltd. (referred to as 'hubei...
Dorui Pharmaceuticals: Report for the third quarter of 2024
Doray Pharmaceuticals (301075.SZ) released its performance for the first three quarters, with a net loss of 17.0787 million yuan.
Doray Pharmaceuticals (301075.SZ) released the report for the first three quarters of 2024, during which the company achieved revenue...
Doray Pharmaceuticals (301075.SZ): The pharmaceutical registration of Ammonium Sulphate Injection has been accepted.
DuoRui Pharmaceutical (301075.SZ) announced that its wholly-owned subsidiary Hubei DuoRui Pharmaceutical Co., Ltd. (referred to as 'hubei...
No Data
No Data